- Home
- AKBA vs SMTI Comparison
AKBA vs SMTI Comparison
Compare AKBA & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- SMTI
- Stock Information
- Founded
- AKBA 2007
- SMTI 1982
- Country
- AKBA United States
- SMTI United States
- Employees
- AKBA N/A
- SMTI N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- SMTI Medical/Dental Instruments
- Sector
- AKBA Health Care
- SMTI Health Care
- Exchange
- AKBA Nasdaq
- SMTI Nasdaq
- Market Cap
- AKBA 336.2M
- SMTI 288.2M
- IPO Year
- AKBA 2014
- SMTI N/A
- Fundamental
- Price
- AKBA $1.91
- SMTI $34.39
- Analyst Decision
- AKBA Strong Buy
- SMTI Buy
- Analyst Count
- AKBA 2
- SMTI 1
- Target Price
- AKBA $5.75
- SMTI $44.00
- AVG Volume (30 Days)
- AKBA 2.3M
- SMTI 24.7K
- Earning Date
- AKBA 11-07-2024
- SMTI 11-12-2024
- Dividend Yield
- AKBA N/A
- SMTI N/A
- EPS Growth
- AKBA N/A
- SMTI N/A
- EPS
- AKBA N/A
- SMTI N/A
- Revenue
- AKBA $169,879,000.00
- SMTI $72,410,222.00
- Revenue This Year
- AKBA N/A
- SMTI $26.97
- Revenue Next Year
- AKBA $3.23
- SMTI $18.91
- P/E Ratio
- AKBA N/A
- SMTI N/A
- Revenue Growth
- AKBA N/A
- SMTI 21.42
- 52 Week Low
- AKBA $0.80
- SMTI $26.00
- 52 Week High
- AKBA $2.48
- SMTI $43.25
- Technical
- Relative Strength Index (RSI)
- AKBA 68.47
- SMTI 64.02
- Support Level
- AKBA $1.30
- SMTI $32.91
- Resistance Level
- AKBA $2.01
- SMTI $34.03
- Average True Range (ATR)
- AKBA 0.12
- SMTI 1.39
- MACD
- AKBA 0.04
- SMTI 0.24
- Stochastic Oscillator
- AKBA 78.52
- SMTI 100.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.